Pleconaril (Synonyms: 普可那利; VP 63843; Win 63843)

目录号: HY-19952 纯度: 99.48%: FAQs
Data Sheet SDS COA 产品使用指南

摩尔计算器

Pleconaril 是一种小核糖核酸病毒衣壳结合抑制剂，可防止病毒附着和/或脱壳。Pleconaril 具有用于研究鼻病毒和肠道病毒的潜力。

MCE 的所有产品仅用作科学研究或药证申报，我们不为任何个人用途提供产品和服务

Pleconaril Chemical Structure

CAS No. : 153168-05-9

1. 客户无需承担相应的运输费用。

2. 同一机构（单位）同一产品试用装仅限申领一次，同一机构（单位）一年内

可免费申领三个不同产品的试用装。

3. 试用装只面向终端客户。

规格	价格	是否有货
10 mM * 1 mL in DMSO	￥968	In-stock
5 mg	￥880	In-stock
10 mg	￥1300	In-stock
50 mg	￥4500	In-stock
100 mg	现货	询价
200 mg	现货	询价
500 mg		询价
1 g		询价

or 大包装询价

* Please select Quantity before adding items.

Customer Review

Other Forms of Pleconaril:

Pleconaril-d₄ 询价
Pleconaril (Standard) 询价

Pleconaril 相关产品

•相关化合物库:

•同靶点产品:

•同靶点蛋白产品:

生物活性
纯度 & 产品资料
参考文献

生物活性

Pleconaril is a picornavirus capsid binding inhibitor that prevents attachment and/or virus uncoating. Pleconaril has potential for use in rhinoviruses and enteroviruses research^[1]^[2].

细胞效力
(Cellular Effect)

Cell Line	Type	Value	Description	References
H1-HeLa	CC₅₀	19.7 μM Compound: Pleconaril	Cytotoxicity against human H1HeLa cells assessed as reduction in cell viability after 3 days by MTT assay Cytotoxicity against human H1HeLa cells assessed as reduction in cell viability after 3 days by MTT assay	[PMID: 30034598]
H1-HeLa	CC₅₀	19.7 μM Compound: 1	Cytotoxicity against human H1HeLa cells assessed as decrease in cell viability after 3 days by MTT assay Cytotoxicity against human H1HeLa cells assessed as decrease in cell viability after 3 days by MTT assay	[PMID: 28581749]
H1-HeLa	CC₅₀	20.8 μM Compound: Pleconaril	Cytotoxicity against human H1-HeLa cells assessed as reduction in cell viability by MTT assay Cytotoxicity against human H1-HeLa cells assessed as reduction in cell viability by MTT assay	[PMID: 35292344]
H1-HeLa	CC₅₀	53.5 μM Compound: Pleconaril	Cytotoxicity in human H1HeLa cells assessed as reduction in cell viability incubated for 3 days by MTT assay Cytotoxicity in human H1HeLa cells assessed as reduction in cell viability incubated for 3 days by MTT assay	[PMID: 28587824]
HeLa	EC₅₀	> 42.8 μM Compound: Pleconaril	Antiviral activity against human coxsackievirus B3 infected in human HeLa cells assessed as reduction in virus-induced cytopathicity incubated for 3 days by MTT assay Antiviral activity against human coxsackievirus B3 infected in human HeLa cells assessed as reduction in virus-induced cytopathicity incubated for 3 days by MTT assay	[PMID: 28587824]
HeLa	IC₅₀	≤ 0.18 μM Compound: 55; WIN63843	Cytotoxicity against human HeLa cells after 3 days by MTT assay Cytotoxicity against human HeLa cells after 3 days by MTT assay	[PMID: 31226653]
HeLa	EC₅₀	0.13 μM Compound: Pleconaril	Antiviral activity against human coxsackievirus B1 infected in human HeLa cells assessed as reduction in virus-induced cytopathicity incubated for 3 days by MTT assay Antiviral activity against human coxsackievirus B1 infected in human HeLa cells assessed as reduction in virus-induced cytopathicity incubated for 3 days by MTT assay	[PMID: 28587824]
HeLa	EC₅₀	0.51 μM Compound: Pleconaril	Antiviral activity against human poliovirus 3 infected in human HeLa cells assessed as reduction in virus-induced cytopathicity incubated for 3 days by MTT assay Antiviral activity against human poliovirus 3 infected in human HeLa cells assessed as reduction in virus-induced cytopathicity incubated for 3 days by MTT assay	[PMID: 28587824]
HeLa	EC₅₀	1.4 μM Compound: 1	Antiviral activity against Human poliovirus 3 infected in human HeLa cells assessed as protection against virus induced cytopathic effect after 2 days by MTT assay Antiviral activity against Human poliovirus 3 infected in human HeLa cells assessed as protection against virus induced cytopathic effect after 2 days by MTT assay	[PMID: 28581749]
HeLa	CC₅₀	12.6 μg/mL Compound: pleconaril	Cytotoxicity against human HeLa cells after 72 hrs Cytotoxicity against human HeLa cells after 72 hrs	[PMID: 18247552]
HeLa	CC₅₀	131 μM Compound: Pleconaril	Cytotoxicity against human HeLa cells assessed as decrease in cell viability after 72 hrs by MTT assay Cytotoxicity against human HeLa cells assessed as decrease in cell viability after 72 hrs by MTT assay	[PMID: 29039946]
HeLa	EC₅₀	177 nM Compound: Pleconaril	Antienteroviral activity against Human rhinovirus 14 infected in human HeLa cells assessed as protection against virus-induced cytopathic effect after 2 to 3 days by MTS assay Antienteroviral activity against Human rhinovirus 14 infected in human HeLa cells assessed as protection against virus-induced cytopathic effect after 2 to 3 days by MTS assay	[PMID: 24900715]
HeLa	EC₅₀	224.1 ng/mL Compound: 1	Antirhinoviral activity against Human rhinovirus B infected in human HeLa cells assessed as inhibition of virus-induced cytopathic effect after 5 days by MTT assay Antirhinoviral activity against Human rhinovirus B infected in human HeLa cells assessed as inhibition of virus-induced cytopathic effect after 5 days by MTT assay	[PMID: 24900468]
HeLa	EC₅₀	23.2 ng/mL Compound: 1	Antirhinoviral activity against minor receptor-resistant Human rhinovirus infected in human HeLa cells assessed as inhibition of virus-induced cytopathic effect after 5 days by MTT assay Antirhinoviral activity against minor receptor-resistant Human rhinovirus infected in human HeLa cells assessed as inhibition of virus-induced cytopathic effect after 5 days by MTT assay	[PMID: 24900468]
HeLa	CC₅₀	25.9 μM Compound: 1	Cytotoxicity aganist human HeLa cells assessed as decrease in cell viability after 2 days by MTT assay Cytotoxicity aganist human HeLa cells assessed as decrease in cell viability after 2 days by MTT assay	[PMID: 28581749]
HeLa	CC₅₀	26.25 μM Compound: Pleconaril	Cytotoxicity against human HeLa cells assessed as reduction in cell viability incubated for 72 hrs measured by crystal violet based micro plate reader method Cytotoxicity against human HeLa cells assessed as reduction in cell viability incubated for 72 hrs measured by crystal violet based micro plate reader method	[PMID: 31881489]
HeLa	EC₅₀	33.8 ng/mL Compound: 1	Antirhinoviral activity against antiviral-resistant Human rhinovirus B infected in human HeLa cells assessed as inhibition of virus-induced cytopathic effect after 5 days by MTT assay Antirhinoviral activity against antiviral-resistant Human rhinovirus B infected in human HeLa cells assessed as inhibition of virus-induced cytopathic effect after 5 days by MTT assay	[PMID: 24900468]
HeLa	EC₅₀	37.4 ng/mL Compound: 1	Antirhinoviral activity against Human rhinovirus A infected in human HeLa cells assessed as inhibition of virus-induced cytopathic effect after 5 days by MTT assay Antirhinoviral activity against Human rhinovirus A infected in human HeLa cells assessed as inhibition of virus-induced cytopathic effect after 5 days by MTT assay	[PMID: 24900468]
HeLa	EC₅₀	387.6 ng/mL Compound: 1	Antirhinoviral activity against antiviral-resistant Human rhinovirus A infected in human HeLa cells assessed as inhibition of virus-induced cytopathic effect after 5 days by MTT assay Antirhinoviral activity against antiviral-resistant Human rhinovirus A infected in human HeLa cells assessed as inhibition of virus-induced cytopathic effect after 5 days by MTT assay	[PMID: 24900468]
HeLa	CC₅₀	42.8 μM Compound: Pleconaril	Cytotoxicity in human HeLa cells assessed as reduction in cell viability incubated for 3 days by MTT assay Cytotoxicity in human HeLa cells assessed as reduction in cell viability incubated for 3 days by MTT assay	[PMID: 28587824]
HeLa	EC₅₀	49.2 ng/mL Compound: 1	Antirhinoviral activity against major receptor-resistant Human rhinovirus infected in human HeLa cells assessed as inhibition of virus-induced cytopathic effect after 5 days by MTT assay Antirhinoviral activity against major receptor-resistant Human rhinovirus infected in human HeLa cells assessed as inhibition of virus-induced cytopathic effect after 5 days by MTT assay	[PMID: 24900468]
RD	CC₅₀	> 200 μM Compound: 1	Cytotoxicity against human RD cells assessed as inhibition of cell viability by measuring ATP level incubated for 72 hrs by cell titer-glo luminescent cell viability assay Cytotoxicity against human RD cells assessed as inhibition of cell viability by measuring ATP level incubated for 72 hrs by cell titer-glo luminescent cell viability assay	[PMID: 36254462]
RD	EC₅₀	13400 nM Compound: Pleconaril	Antienteroviral activity against Enterovirus 71 infected in human RD cells assessed as protection against virus-induced cytopathic effect after 2 to 3 days by MTS assay Antienteroviral activity against Enterovirus 71 infected in human RD cells assessed as protection against virus-induced cytopathic effect after 2 to 3 days by MTS assay	[PMID: 24900715]
Vero	EC₅₀	0.002 μM Compound: Pleconaril	Antiviral activity against Coxsackievirus B3 infected in Vero cells assessed as reduction in virus-induced cytopathic effect incubated for 48 hrs by Reed-Muench method Antiviral activity against Coxsackievirus B3 infected in Vero cells assessed as reduction in virus-induced cytopathic effect incubated for 48 hrs by Reed-Muench method	[PMID: 32378892]
Vero	EC₅₀	0.005 μM Compound: Pleconaril	Antiviral activity against Coxsackievirus B5 infected in African green monkey Vero 76 cells after 3 days by plaque reduction assay Antiviral activity against Coxsackievirus B5 infected in African green monkey Vero 76 cells after 3 days by plaque reduction assay	[PMID: 25913116]
Vero	EC₅₀	1084 nM Compound: Pleconaril	Antienteroviral activity against poliovirus 2 infected in african green monkey Vero cells assessed as protection against virus-induced cytopathic effect after 2 to 3 days by MTS assay Antienteroviral activity against poliovirus 2 infected in african green monkey Vero cells assessed as protection against virus-induced cytopathic effect after 2 to 3 days by MTS assay	[PMID: 24900715]
Vero	EC₅₀	13000 nM Compound: Pleconaril	Antienteroviral activity against Coxsackievirus B3 infected in african green monkey Vero cells assessed as protection against virus-induced cytopathic effect after 2 to 3 days by MTS assay Antienteroviral activity against Coxsackievirus B3 infected in african green monkey Vero cells assessed as protection against virus-induced cytopathic effect after 2 to 3 days by MTS assay	[PMID: 24900715]
Vero	EC₅₀	2.2 μM Compound: Pleconaril	Antiviral activity against Poliovirus Sb-1 infected in African green monkey Vero 76 cells after 2 days by plaque reduction assay Antiviral activity against Poliovirus Sb-1 infected in African green monkey Vero 76 cells after 2 days by plaque reduction assay	[PMID: 25913116]
Vero	EC₅₀	24200 nM Compound: Pleconaril	Antienteroviral activity against poliovirus 1 infected in african green monkey Vero cells assessed as protection against virus-induced cytopathic effect after 2 to 3 days by MTS assay Antienteroviral activity against poliovirus 1 infected in african green monkey Vero cells assessed as protection against virus-induced cytopathic effect after 2 to 3 days by MTS assay	[PMID: 24900715]
Vero	EC₅₀	33 nM Compound: Pleconaril	Antienteroviral activity against Coxsackievirus A9 infected in african green monkey Vero cells assessed as protection against virus-induced cytopathic effect after 2 to 3 days by MTS assay Antienteroviral activity against Coxsackievirus A9 infected in african green monkey Vero cells assessed as protection against virus-induced cytopathic effect after 2 to 3 days by MTS assay	[PMID: 24900715]
Vero	EC₅₀	84 nM Compound: Pleconaril	Antienteroviral activity against poliovirus 3 infected in african green monkey Vero cells assessed as protection against virus-induced cytopathic effect after 2 to 3 days by MTS assay Antienteroviral activity against poliovirus 3 infected in african green monkey Vero cells assessed as protection against virus-induced cytopathic effect after 2 to 3 days by MTS assay	[PMID: 24900715]
Vero 76	CC₅₀	> 100 μM Compound: Pleconaril	Cytotoxicity against African green monkey Vero 76 cells assessed as reduction in cell viability after 48 to 96 hrs by MTT assay Cytotoxicity against African green monkey Vero 76 cells assessed as reduction in cell viability after 48 to 96 hrs by MTT assay	[PMID: 29339251]
Vero 76	EC₅₀	0.008 μM Compound: Pleconaril	Antiviral activity against human CVB5 infected in african green monkey Vero76 cells assessed as inhibition of virus-induced cytopathogenicity after 3 days by plaque reduction assay Antiviral activity against human CVB5 infected in african green monkey Vero76 cells assessed as inhibition of virus-induced cytopathogenicity after 3 days by plaque reduction assay	[PMID: 26443549]
Vero 76	EC₅₀	2 μM Compound: Pleconaril	Antiviral activity against Human poliovirus 1 Sabin infected in african green monkey Vero76 cells assessed as inhibition of virus-induced cytopathogenicity by plaque reduction assay Antiviral activity against Human poliovirus 1 Sabin infected in african green monkey Vero76 cells assessed as inhibition of virus-induced cytopathogenicity by plaque reduction assay	[PMID: 26443549]
Vero 76	CC₅₀	70 μM Compound: Pleconaril	Cytotoxicity against african green monkey Vero 76 cells assessed as cell viability after 48 to 96 hrs by crystal violet staining method Cytotoxicity against african green monkey Vero 76 cells assessed as cell viability after 48 to 96 hrs by crystal violet staining method	[PMID: 26443549]
Vero 76	CC₅₀	80 μM Compound: Pleconaril	Cytotoxicity against African green monkey Vero 76 cells assessed as cell viability after 48 to 96 hrs by MTT method Cytotoxicity against African green monkey Vero 76 cells assessed as cell viability after 48 to 96 hrs by MTT method	[PMID: 25913116]
Vero 76	CC₅₀	83 μM Compound: Pleconaril	Cytotoxicity against African green monkey Vero 76 cells assessed as decrease in cell viability after 48 to 96 hrs by MTT assay Cytotoxicity against African green monkey Vero 76 cells assessed as decrease in cell viability after 48 to 96 hrs by MTT assay	[PMID: 29028528]

体外研究
(In Vitro)

Pleconaril (0.4-50 µM，2 天) 在 RD 细胞中在 50 µM 浓度下产生显著的细胞毒性^[2]。
Pleconaril (0.001-4 µg/mL, 24 小时) 可提高感染 EV71 的 RD 细胞的细胞活力^[3]。

MCE has not independently confirmed the accuracy of these methods. They are for reference only.

体内研究
(In Vivo)

Pleconaril (2-200 mg/kg，腹腔注射，每日一次，5 天) 可增加感染 EV71 的小鼠的存活数量^[3]。

MCE has not independently confirmed the accuracy of these methods. They are for reference only.

Clinical Trial

分子量

381.35

Formula

C₁₈H₁₈F₃N₃O₃

CAS 号

153168-05-9

性状

固体

颜色

White to off-white

中文名称

普可那利

运输条件

Room temperature in continental US; may vary elsewhere.

储存方式

Powder	-20°C	3 years
	4°C	2 years
In solvent	-80°C	2 years
	-20°C	1 year

溶解性数据

细胞实验：

DMSO 中的溶解度 : 100 mg/mL (262.23 mM; 超声助溶; 吸湿的 DMSO 对产品的溶解度有显著影响，请使用新开封的 DMSO)

配制储备液

浓度溶剂体积质量	1 mg	5 mg	10 mg

1 mM	2.6223 mL	13.1113 mL	26.2226 mL
5 mM	0.5245 mL	2.6223 mL	5.2445 mL
10 mM	0.2622 mL	1.3111 mL	2.6223 mL

查看完整储备液配制表

* 请根据产品在不同溶剂中的溶解度选择合适的溶剂配制储备液；一旦配成溶液，请分装保存，避免反复冻融造成的产品失效。
储备液的保存方式和期限：-80°C, 2 years; -20°C, 1 year。-80°C储存时，请在2年内使用， -20°C储存时，请在1年内使用。

摩尔计算器
稀释计算器

Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

Concentration _(start) × Volume _(start) = Concentration _(final) × Volume _(final)

This equation is commonly abbreviated as: C₁V₁ = C₂V₂

浓度 _(start)

体积 _(start)

浓度 _(final)

体积 _(final)

动物实验：

请根据您的实验动物和给药方式选择适当的溶解方案。

以下溶解方案都请先按照 In Vitro 方式配制澄清的储备液，再依次添加助溶剂：
——为保证实验结果的可靠性，澄清的储备液可以根据储存条件，适当保存；体内实验的工作液，建议您现用现配，当天使用；
以下溶剂前显示的百分比是指该溶剂在您配制终溶液中的体积占比；如在配制过程中出现沉淀、析出现象，可以通过加热和/或超声的方式助溶

方案一

请依序添加每种溶剂： 10% DMSO 40% PEG300 5% Tween-80 45% Saline
Solubility: ≥ 2.5 mg/mL (6.56 mM); 澄清溶液

此方案可获得 ≥ 2.5 mg/mL（饱和度未知）的澄清溶液。
以 1 mL 工作液为例，取 100 μL 25.0 mg/mL 的澄清 DMSO 储备液加到 400 μL PEG300 中，混合均匀；再向上述体系中加入 50 μL Tween-80，混合均匀；然后再继续加入 450 μL 生理盐水定容至 1 mL。
生理盐水的配制：将 0.9 g 氯化钠，溶解于 ddH₂O 并定容至 100 mL，可以得到澄清透明的生理盐水溶液。
方案二

请依序添加每种溶剂： 10% DMSO 90% Corn Oil
Solubility: ≥ 2.5 mg/mL (6.56 mM); 澄清溶液

此方案可获得 ≥ 2.5 mg/mL（饱和度未知）的澄清溶液，此方案实验周期在半个月以上的动物实验酌情使用。
以 1 mL 工作液为例，取 100 μL 25.0 mg/mL 的澄清 DMSO 储备液加到 900 μL玉米油中，混合均匀。

动物溶解方案计算器

请输入动物实验的基本信息：

给药剂量

mg/kg

动物的平均体重

每只动物的给药体积

μL

动物数量

只

由于实验过程有损耗，建议您多配一只动物的量

请输入您的动物体内配方组成：

DMSO +

Tween-80 +

Saline

如果您的动物是免疫缺陷鼠或者体弱鼠，建议 DMSO 中的在最后工作液体系中的占比尽量不超过 2%。

方案所需 助溶剂 包括：DMSO，，均可在 MCE 网站选购。，Tween 80，均可在 MCE 网站选购。

计算结果

工作液所需浓度 : mg/mL

储备液配制方法 : mg 药物溶于 μL DMSO（母液浓度为 mg/mL）。

您所需的储备液浓度超过该产品的实测溶解度，以下方案仅供参考，如有需要，请与 MCE 中国技术支持联系。

动物实验体内工作液的配制方法 : 取 μL DMSO 储备液，加入 μL 。 μL ，混合均匀至澄清，再加 μL Tween 80，混合均匀至澄清，再加 μL 生理盐水。

连续给药周期超过半月以上，请谨慎选择该方案。

请确保第一步储备液溶解至澄清状态，从左到右依次添加助溶剂。您可采用超声加热（超声清洗仪，建议频次 20-40 kHz），涡旋吹打等方式辅助溶解。

纯度 & 产品资料

纯度: 99.48%

选择批次：

Data Sheet (623 KB) SDS (479 KB)

COA (283 KB) LCMS (95 KB)

产品使用指南 (1538 KB)

参考文献

[1]. Benschop KS, et al. Genetic and antigenic structural characterization for resistance of echovirus 11 to pleconaril in an immunocompromised patient. J Gen Virol. 2015 Mar;96(Pt 3):571-9. [Content Brief]

[2]. Lee JS, et al. Antiviral Activity of Itraconazole against Echovirus 30 Infection In Vitro. Osong Public Health Res Perspect. 2017 Oct;8(5):318-324. [Content Brief]

[3]. Zhang G, et al. In vitro and in vivo evaluation of ribavirin and pleconaril antiviral activity against enterovirus 71 infection. Arch Virol. 2012 Apr;157(4):669-79. [Content Brief]

Pleconaril 相关分类

Infection

完整储备液配制表

可选溶剂	浓度溶剂体积质量	1 mg	5 mg	10 mg	25 mg

DMSO	1 mM	2.6223 mL	13.1113 mL	26.2226 mL	65.5566 mL
	5 mM	0.5245 mL	2.6223 mL	5.2445 mL	13.1113 mL
	10 mM	0.2622 mL	1.3111 mL	2.6223 mL	6.5557 mL
	15 mM	0.1748 mL	0.8741 mL	1.7482 mL	4.3704 mL
	20 mM	0.1311 mL	0.6556 mL	1.3111 mL	3.2778 mL
	25 mM	0.1049 mL	0.5245 mL	1.0489 mL	2.6223 mL
	30 mM	0.0874 mL	0.4370 mL	0.8741 mL	2.1852 mL
	40 mM	0.0656 mL	0.3278 mL	0.6556 mL	1.6389 mL
	50 mM	0.0524 mL	0.2622 mL	0.5245 mL	1.3111 mL
	60 mM	0.0437 mL	0.2185 mL	0.4370 mL	1.0926 mL
	80 mM	0.0328 mL	0.1639 mL	0.3278 mL	0.8195 mL
	100 mM	0.0262 mL	0.1311 mL	0.2622 mL	0.6556 mL

Help & FAQs

Do most proteins show cross-species activity?
Species cross-reactivity must be investigated individually for each product. Many human cytokines will produce a nice response in mouse cell lines, and many mouse proteins will show activity on human cells. Other proteins may have a lower specific activity when used in the opposite species.

产品名称：			* 需求量：
* 客户姓名：			* Email：
* 电话：			* 公司或机构名称：
留言给我们：

产品名称：			* Lot #：
* 客户姓名：			* Email：
电话：			* 部门：
* 公司或机构名称：
留言给我们：

MedChemExpress (MCE) 只为有资质的科研机构、医药企业基于科学研究或药证申报的用途提供医药研发服务，不为任何个人或者非科研性质的、非用于药证申报使用等其他用途提供服务。	站点地图隐私声明
沪ICP备15051369号-4 上海工商沪公网安备31011502019417 沪(浦)应急管危经许[2021]201709(QFYS) 营业执照（三证合一）
Copyright © 2013-2024 MedChemExpress. All Rights Reserved.

Pleconaril (Synonyms: 普可那利; VP 63843; Win 63843)

Customer Review

Other Forms of Pleconaril:

Pleconaril 相关产品

•相关化合物库:

•同靶点产品:

•同靶点蛋白产品:

生物活性

纯度 & 产品资料

参考文献

摩尔计算器

稀释计算器

Pleconaril 相关分类

完整储备液配制表

Keywords:

您最近查看的产品:

热门区域

A

B

C

F

G

H

J

L

N

Q

S

T

X

Y

Z

姓名
邮箱 *

Sorry, but the email address you supplied was invalid.

Pleconaril (Synonyms: 普可那利; VP 63843; Win 63843)

Customer Review

Other Forms of Pleconaril:

Pleconaril 相关抗体

Pleconaril 相关产品

•相关化合物库:

•同靶点产品:

•同靶点蛋白产品:

生物活性

纯度 & 产品资料

参考文献

Pleconaril 相关抗体:

摩尔计算器

稀释计算器

Pleconaril 相关分类

完整储备液配制表

Keywords:

您最近查看的产品:

Request for HNMR Report

Request for HNMR Report

热门区域

A

B

C

F

G

H

J

L

N

Q

S

T

X

Y

Z